Hong Kong stock movement: TRANSTHERA-B rose 12.10%, with active capital flow, raising market attention on sector trends?

Hong Kong Stock Movement TRANSTHERA-B rose 12.10%, with no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Stocks with High Trading Volume in the Industry 3SBio rose 10.62%, with a trading volume reaching HKD 1.202 billion, and no significant news recently. The trading is active, and the capital flow is evident. Considering the sector and industry trends, the stock shows significant volatility, and the specific reasons need further observation. Innovent Biologics rose 6.88%. Based on recent key news: On October 30, Innovent Biologics participated in the national medical insurance catalog negotiation, boosting market confidence. As one of the first companies to enter, Innovent participated in the 2025 national medical insurance catalog negotiation, enhancing investors' confidence in its future market performance, driving the stock price up. On October 30, Innovent Biologics reported a 40% increase in third-quarter revenue, driven by oncology and comprehensive pipeline dual engines. The company announced that total product revenue in the third quarter exceeded RMB 3.3 billion, a year-on-year increase of about 40%. It maintains a leading position in the oncology treatment field, with the contribution of innovative product revenue further increasing, driving the stock price up. On October 30, Innovent Biologics collaborated with Takeda Pharmaceutical to develop IBI363, and the market is optimistic about its long-term development. Innovent adopts a "Co-Co" model to jointly develop IBI363 with Takeda. Although there are concerns about costs in the market, the company emphasizes its focus on long-term development, enhancing investor confidence. The innovative drug sector continues to adjust, focusing on long-term value. Kangfang Biotech rose 3.16%. Based on recent news: On October 30, Kangfang Biotech announced the Phase III clinical trial results of the HARMONi-A study, showing highly positive results in overall survival for its novel bispecific antibody ivonescimab (PD-1/VEGF bispecific antibody). This breakthrough progress has enhanced investor confidence, driving the stock price up. On October 28, Kangfang Biotech announced that one of its studies will start on November 14, 2024, which may trigger investor interest and affect market entry. Successful results from the study may further enhance investor confidence and market positioning. No other significant news recently. The biopharmaceutical industry has performed strongly recently, and investors are focused on new drug development progress. Stocks with High Market Capitalization in the Industry BeiGene rose 2.27%. Based on recent key news: On October 28, HSBC Research lowered BeiGene's third-quarter revenue forecast by 3%, but maintained a buy rating due to long-term competitive advantages. Despite increased market competition, HSBC believes that the overseas launch of BeiGene's BTK and BCL-2 products will offset some of the impacts. On October 29, Guotai Junan Securities pointed out that China's innovative drug industry has a long-term positive outlook, with significant growth in BD transactions. Although the difficulty of innovative drugs going overseas has increased, domestic assets still have advantages, and the adjustment in the innovative drug sector has basically reached its limit On October 28th, according to data from Artery Network, the return rate for License-out transactions reached as high as 40%, but the long-term investment value of the innovative drug industry chain is still optimistic. The innovative drug sector is adjusting, and its long-term investment value is becoming apparent